Intensive blood pressure-lowering treatment

2 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funders: Cyrus Tang Foundation and 2 more

Human trial1

Outcomes

Systolic blood pressure

downin humans1

1 study

Intensive blood pressure-lowering treatment decreases systolic blood pressure in humans (11·2 mm Hg (95% CI 10·7-11·7)).
Reviewover median follow-up of 42.0 months42·0 monthsn = 2,944
Intensive blood pressure lowering after spontaneous intracerebral haemorrhage for secondary stroke prevention (RECAP-ICH): a systematic review and individual participant data meta-analysis
The Lancet. Neurology12 Aug 2026

Associations

Mild cognitive impairment

downin humans1HR 0.64

1 study

Intensive blood pressure-lowering treatment lowers the risk of mild cognitive impairment in humans (adjusted HR 0.64, 95% CI 0.48-0.86).
Human trialfavourable cardiometabolic renal health profilesn = 8,162
Cardiometabolic Renal Health Profile, Intensive Blood Pressure-Lowering Treatment and Cognitive Dysfunction: A Post Hoc Analysis of the SPRINT Trial
Diabetes, obesity & metabolism12 Aug 2026